

Organized by



5th Annual Review on Head & Neck Cancers

5th, 6th & 7th August, 2022

Organizing Chairpersons

Dr. B. K. Smruti

Dr. Vijay Haribhakti

Dr. Kumar Prabhash

Organizing Secretaries

Dr. Mandar Deshpande

Dr. Sewanti Limaye

Dr. Kaustav Talapatra

Dr. Prasad Dandekar

Scientific Committee Chair

Dr. Vanita Noronha

Dr. Vijay Patil



Venue

Courtyard by Marriott,
Mumbai

For registration visit

<https://www.riverroute.in/arhnc2022>

Managed by
riverroute
Leaders in Streaming Modules

Organized by



5th Annual Review on Head & Neck Cancers

5th, 6th & 7th August, 2022

Welcome Address

On behalf of the organizing committee and Mumbai Oncology Association, we are pleased to invite you to the **"5th Annual Review on Head and Neck Cancers Conference"**. This will be a hybrid conference and will be held on **05 (Virtual), 06 & 07 (Hybrid) August 2022**

The 5th Annual Review on Head and Neck Cancers Conference 2022 will provide practitioners an update in head and neck cancers with a comprehensive overview of the current standard of care practices as well as review of evolving and innovative treatment approaches. Management recommendations are rapidly evolving in this era of immune oncology and will receive particular attention, including a discussion of de-escalation and the current randomised trials evaluating de-escalation protocols.

The focus of this conference will be on latest in multidisciplinary approach to head and neck treatment, novel treatment breakthroughs and leading research publications and current best practices in supportive and survivorship care.

Distinguished faculty from Mumbai as well as from prominent National faculty will present a series of recent important publications followed by open panels which cover the management of malignancies in critical subsites within the head and neck such as the oral cavity, oropharynx, larynx, thyroid, and others. We will also cover important publications on rare subjects in head and neck cancers.

Open interaction between faculty and participants will be encouraged throughout the sessions. Participants are encouraged to pre-submit important problem statements needing Indian consensus.

We look forward to your active participation.

Regards

Organising Team

For registration visit

<https://www.riverroute.in/arhnc2022>

Managed by
riverroute
Leaders in Streaming Modules

Organized by



5th Annual Review on Head & Neck Cancers

5th, 6th & 7th August, 2022

5th August 2022

Day 1 (Virtual Hall A)

6:30 pm - 7:00 pm

Role of LBx in H&N Cancers

Speaker : Dr. Avik Mukherjee

7.00 pm - 7.30 pm

Rationale of PD-L 1 CPS as predictive biomarker
in HNSCC (Supported by MSD)

Speaker : Dr. Nandini Menon

For registration visit

<https://www.riveroute.in/arhnc2022>

Managed by
riveroute
Leaders in Streaming Modules

Organized by



5th Annual Review on Head & Neck Cancers

5th, 6th & 7th August, 2022

6th August 2022

Day 2 Hybrid

08.00 am - 09.00 am	Registration
09.00 am - 10.25 am	Session 1: Key Publication On Oral Cancer
09.00 am - 09.10 am	<p>Chairpersons : Dr. S. K. Shrivastava Dr. Deepak Parikh</p> <p>Reviewer : Dr. Ajaykumar Singh</p> <ul style="list-style-type: none">Phase 3 randomized study comparing docetaxel-platinum with docetaxel-platinum-5 fluorouracil as neoadjuvant chemotherapy in technically unresectable oral cancer Author : Ajaykumar Singh Citation : Journal of Clinical Oncology 2022 40:16_suppl, 6013-6013Intensifying adjuvant therapy in advanced oral cavity carcinoma: Result of randomized study Author: Sarbani Ghos Laskar Citation: Green journal-Radiotherapy & Oncology
09.10 am - 09.20 am	<p>Reviewer : Dr. H. Yathiraj Prahlad</p> <ul style="list-style-type: none">Results from a prospective, randomised study on (accelerated) preoperative versus (conventional) postoperative radiotherapy in treatment of patients with resectable squamous cell carcinoma of the oral cavity – The ARTSCAN 2 study Author : Johan Wennerberg Citation : Radiother Oncol. 2022 Jan;166:26-32Neoadjuvant Chemoradiotherapy for Oral Cavity Cancer: Predictive Factors for Response and Interim Analysis of the Prospective INVERT-Trial Author : Jens von der Grün Citation : Front Oncol. 2022; 12: 817692

For registration visit

<https://www.riveroute.in/arhnc2022>

Managed by
riveroute
Leaders in Streaming Modules

Organized by



5th Annual Review on Head & Neck Cancers

5th, 6th & 7th August, 2022

6th August 2022 — Day 2 Hybrid

09.20 am - 09.30 am

Reviewer : Dr. Shilpi Sharma

- Prospective Phase II Open-Label Randomized Controlled Trial to Compare Mandibular Preservation in Upfront Surgery with Neoadjuvant Chemotherapy Followed by Surgery in Operable Oral Cavity Cancer

Author : Devendra Chaukar

Citation : Journal of Clinical Oncology 40, no. 3 (January 20, 2022) 272-281

- Effect of elective neck dissection versus sentinel lymph node biopsy on shoulder morbidity and health-related quality of life in patients with oral cavity cancer: A longitudinal comparative cohort study

Author: Gerben van Hinte

Citation: Oral Oncol. 2021 Nov;122:105510

09.30 am - 09.40 am

Reviewer : Dr. Nikhil Dharmadhikari

- Hyperbaric oxygen treatment of mandibular osteoradionecrosis: Combined data from the two randomized clinical trials DAHANCA-21 and NWHHT2009-1

Author : Lone E Forner

Citation : Radiother Oncol. 2022 Jan;166:137-144

- Transoral robotic surgery with neck dissection versus nonsurgical treatment in stage I and II human papillomavirus-negative oropharyngeal cancer

Author : Bollig CA

Citation : Head Neck. 2022 Jul;44(7):1545-1553. doi: 10.1002/hed.27045

For registration visit

<https://www.riveroute.in/arhnc2022>

Managed by
riveroute
Leaders in Streaming Modules

Organized by



5th Annual Review on Head & Neck Cancers

5th, 6th & 7th August, 2022

6th August 2022

Day 2 Hybrid

09.40 am - 09.50 am

Reviewer : Dr. Pritam Kataria

- Effectiveness of adjuvant chemoradiotherapy for oral cavity squamous cell carcinoma with minor and major extranodal extension: A multi-institutional consortium study
Author : Mirko Manojlovic Kolarski
Citation : Journal of Clinical Oncology 2022 40:16_suppl, 6010-6010
- Prognostic Value of Lymph Node Density in Node-Positive Oral Squamous Cell Carcinoma
Author: Amol Padegaonkar
Citation: Indian Journal of Surgical Oncology (2021)

09.50 am - 10.20 am

**Chairpersons : Dr. Prakash Ramachandra
Dr. Vicky Khattar**

- Panel Discussion On Oral Cancer
Moderator : Dr. Arvind Krishnamurthy
Panelists : Dr. Amol Dongre
Dr. Anuja Deshmukh
Dr. Ashok Shenoy
Dr. Ashwini Budrukhar
Dr. Murad Lala
Dr. Samir Batham
Dr. Sanjay Joshi
Dr. Manoj Mahajan

10.20 am - 10.40 am

TEA/COFFEE BREAK

For registration visit

<https://www.riveroute.in/arhnc2022>

Managed by
riveroute
Leaders in Streaming Modules

Organized by



5th Annual Review on Head & Neck Cancers

5th, 6th & 7th August, 2022

6th August 2022

Day 2 Hybrid

10.40 am - 11.50 am

Session 2: Key Publication on Laryngeal and Oropharyngeal Cancers

10.40 am - 10.50 am

**Chairpersons : Dr. Vivek Kaushal
Dr. Shekhar Salkar**

Reviewer : Dr. Monali Swain

- Randomized Trial of Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Long-Term Results of the ORATOR Trial

Author : Anthony C Nichols

Citation : Journal of Clinical Oncology 40, no. 8 (March 10, 2022) 866-875

- Survival and Larynx Preservation in Early Glottic Cancer: A Randomized Trial Comparing Laser Surgery and Radiation Therapy

Author : Pakkanen, Pihla et al.

Citation: International Journal of Radiation Oncology, Biology, Physics, Volume 113, Issue 1, 96 - 100

10.50 am - 11.00 am

Reviewer : Dr. Shwetabh Sinha

- Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01) - A Trans-Tasman Radiation Oncology Group Study

Author : Rischin, Danny et al

Citation : International Journal of Radiation Oncology, Biology, Physics, Volume 111, Issue 4, 876 - 886

- Result from compare phase III RCT: Dose escalated chemoradiation Vs control in oropharyngeal cancer

Author : Paul Sanghera

Citation: ICHNO-ECHNO 2022: OC-0014

For registration visit

<https://www.riveroute.in/arhnc2022>

Managed by
riveroute
Leaders in Streaming Modules

Organized by



5th Annual Review on Head & Neck Cancers

5th, 6th & 7th August, 2022

6th August 2022

Day 2 Hybrid

11.00 am - 11.10 am

Reviewer : Dr. Shivakumar Thiagarajan

- LBA-3: Patient-reported Outcomes in Oropharyngeal Cancer Treated With Definitive Chemoradiation vs. Surgery With Postoperative Radiation With or Without Chemotherapy

Author : M.W. McDonald

Citation : IJROBP 2022: LBA-3: VOLUME 113;ISSUE 1; E2

- Survival analysis of patients with advanced hypopharyngeal cancer comparing patients who received primary surgery to those who received chemoradiation: An analysis of the NCDB

Author : Colleen G. Hochfelde

Citation: Oral Oncol. 2021 Oct;121:105470

11.10 am - 11.15 am

Reviewer : Dr. Nikhil Kalyani

- Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trial

Author : Nutting, Christopher M. et al

Citation : European Journal of Cancer, Volume 153, 242 - 256

11.15 am - 11.20 am

Reviewer : Dr. Deepak Balasubramanian

- Robotic surgery may improve overall survival for T1 and T2 tumors of the hypopharynx: An NCDB cohort study

Author : Andrey Finegersh

Citation : Oral Oncol. 2021 Oct;121:105440

For registration visit

<https://www.riverroute.in/arhnc2022>

Managed by
riverroute
Leaders in Streaming Modules

Organized by



5th Annual Review on Head & Neck Cancers

5th, 6th & 7th August, 2022

6th August 2022

Day 2 Hybrid

11.20 am - 11.50 am

**Chairpersons : Dr. Sandeep De
Dr. Sudeep Sarkar**

- Panel Discussion on Laryngeal & Oropharyngeal Cancer

Moderator : Dr. Vikram Kekatpure

**Panelists : Dr. Rakesh Neve
Dr. Poonam Joshi
Dr. Akshay Kudpaje
Dr. Gunjan Baijal
Dr. Narayan Prasad
Dr. Venkat Radhakrishnan
Dr. Sudhir Nair**

11.50 am - 01.05 pm

Session 3: Key Publication on Nasopharyngeal Cancer

**Chairpersons : Dr. Kaustubh Patel
Dr. Sumit Basu**

11.50 am - 12.05 pm

Reviewer : Dr. Vijay Patil

- Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial
Author : Naomi Kiyota
Citation : Journal of Clinical Oncology 40, no.18;1980-1990

- Results of phase 3 randomized trial for use of docetaxel as a radiosensitizer in patients with head and neck cancer unsuitable for cisplatin-based chemoradiation
Author : Vijay Maruti Patil
Citation : Journal of Clinical Oncology 2022;LBA6003-LBA6003

For registration visit

<https://www.riveroute.in/arhnc2022>

Managed by
riveroute
Leaders in Streaming Modules

Organized by



5th Annual Review on Head & Neck Cancers

5th, 6th & 7th August, 2022

6th August 2022

Day 2 Hybrid

12.05 pm - 12.15 pm

- Phase 3 randomized study evaluating the addition of low-dose nivolumab to palliative chemotherapy in head and neck cancer
Author : Vijay Maruti Patil
Citation : Journal of Clinical Oncology 2022; LBA6016

Reviewer : Dr. Swapnil Rane

- A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma
Author : Lee, Anne W.M. et al.
Citation : European Journal of Cancer, Volume 153, 109 - 122

12.15 pm - 12.25 pm

- Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial
Author : Xiao-Yun Li
Citation : Journal of Clinical Oncology 40, no. 11 (April 10, 2022) 1163-1173

Reviewer : Dr. Gagan Saini

- A Randomized Controlled Trial of Reirradiation Using Diffusion-Weighted MRI Guided Dose-Painting vs. CT-Based Radiotherapy for Locally Recurrent T3 to T4 Nasopharyngeal Carcinoma
Author : Liu, F. et al.
Citation : International Journal of Radiation Oncology, Biology, Physics, Volume 111, Issue 3, S63

For registration visit

<https://www.riveroute.in/arhnc2022>

Managed by
riveroute
Leaders in Streaming Modules

Organized by



5th Annual Review on Head & Neck Cancers

5th, 6th & 7th August, 2022

6th August 2022

Day 2 Hybrid

12.25 pm - 12.35 pm

- Five-Year Result After Reduction of the Target Volume of Intensity Modulated Radiotherapy Following Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase 3, Multicenter, Randomized Controlled Trial
Author : Xiang, L. et al.
Citation : International Journal of Radiation Oncology, Biology, Physics, Volume 111, Issue 3, S142
- **Reviewer : Dr. Akhil Kapoor**
Management of suboptimal response to induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Re-induction therapy or direct to Radiotherapy?
Author : Ting Liu
Citation : Radiother Oncol. 2021 Oct;163:185-191
- MRI-based radiomics to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A multicenter study
Author : Hesong Shen
Citation : Radiother Oncol. 2022 Jun;171:107-113

For registration visit

<https://www.riveroute.in/arhnc2022>

Managed by
riveroute
Leaders in Streaming Modules

Organized by



5th Annual Review on Head & Neck Cancers

5th, 6th & 7th August, 2022

6th August 2022

Day 2 Hybrid

12.35 pm - 01.05 pm

Chairpersons : Dr. Asha Kapadia
Dr. G. V. Giri

- Panel Discussion on Nasopharyngeal Cancer

Moderator : Dr. Sarbani Laskar

Panelists : Dr. Deepa Nair
Dr. Devang Bhavsar
Dr. Devendra Chaukar
Dr. Vikas Talreja
Dr. Sayan Paul
Dr. Shekhar Keshri

01.05 pm - 02.05 pm

BREAK

01.30 pm - 02.00 pm

Role of IO and its sequencing strategy in the management of HNSCC (Supported by MSD)
Speaker : Dr. Ashay Karpe

02.05 pm - 03.05 pm

Session 4: Key Publication on Salivary Gland Cancer

02.05 pm - 02.15 pm

Chairpersons : Dr. Yogesh Dabholkar
Dr. Harsh Dhar

- Reviewer :** Dr. Richa Vaish

Evaluation of Surgical Margin Status in Patients With Salivary Gland Cancer

Author : Martin Hanson

Citation : JAMA Otolaryngol Head Neck Surg. 2022;148(2):128-138

- Evaluation of Parotidectomy Defect Reconstruction: A Systematic Review And Metaanalysis

Author : Jacob S Brady

Citation : AHNS 2022: Poster: A135

For registration visit

<https://www.riverroute.in/arhnc2022>

Managed by
riverroute
Leaders in Streaming Modules

Organized by



5th Annual Review on Head & Neck Cancers

5th, 6th & 7th August, 2022

6th August 2022 — Day 2 Hybrid

02.15 pm - 02.25 pm

Reviewer : Dr. Kinjal Jani

Parotid Gland Stem Cell Sparing Radiation Therapy for Patients With Head and Neck Cancer: A Double-Blind Randomized Controlled Trial

Author : Steenbakkers, Roel J.H.M. et al

Citation : International Journal of Radiation Oncology, Biology, Physics, Volume 112, Issue 2, 306 - 316

The impact of head and neck radiotherapy on salivary flow and quality of life: Results of the ORARAD study

Author : Alexander Lin

Citation : Oral Oncol. 2022 Apr; 127:105783

02.25 pm - 02.35 pm

Reviewer : Dr. M. V. Chandrakanth

A phase II trial of all-trans retinoic acid (ATRA) in advanced adenoid cystic carcinoma

Author : Glenn J. Hanna

Citation : Oral Oncol. 2021 Aug;119:105366

Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial

Author : Laura D Locati

Citation : Journal of Clinical Oncology 39, no. 36 (December 20, 2021) 4061-4068

For registration visit

<https://www.riverroute.in/arhnc2022>

Managed by
riverroute
Leaders in Streaming Modules

Organized by



5th Annual Review on Head & Neck Cancers

5th, 6th & 7th August, 2022

6th August 2022

Day 2 Hybrid

02.35 pm - 03.05 pm

**Chairpersons : Dr. Punita Lal
Dr. Umang Mittal**

• Panel Discussion on Salivary Gland Cancer

Moderator : Dr. Prathamesh Pai

**Panelists : Dr. Vishal Rao
Dr. Subramanian Iyer
Dr. Rohit Malde
Dr. Ajeet Gandhi
Dr. Tushar Patil
Dr. Suhail Sayed
Dr. Pankaj Chaturvedi
Dr. Trinanjan Basu**

03.05 pm - 04.05 pm

Session 5: Key Publication on Thyroid Cancer

**Chairpersons : Dr. K. Pavithran
Dr. Ashok Shenoy**

03.05 pm - 03.15 pm

Reviewer : Dr. Sunil Chopade

• Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial

Author : Prof. Marcia S Brose

Citation : VOLUME 22, ISSUE 8, P1126-1138, AUGUST 01, 2021

• Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

Author : V. Subbiah

Citation : Ann Oncol. 2022 Apr;33(4):406-415

For registration visit

<https://www.riverroute.in/arhnc2022>

Managed by
riverroute
Leaders in Streaming Modules

Organized by



5th Annual Review on Head & Neck Cancers

5th, 6th & 7th August, 2022

6th August 2022

Day 2 Hybrid

03.15 pm - 03.25 pm

Reviewer : Dr. Apurva Garg

- Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer

Author : Sophie Leboulleux

Citation : N Engl J Med. 2022 Mar 10;386(10):923-932

- Prophylactic Central Neck Dissection for cN1b Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis

Author : Xing-Qiang Yan

Citation : Front Oncol. 2022 Jan 14;11:803986

03.25 pm - 03.35 pm

Reviewer : Dr. Vikas Talreja

- Association of Multifocality With Prognosis of Papillary Thyroid Carcinoma A Systematic Review and Meta-analysis

Author : Hyeonkyeong Kim

Citation : JAMA Otolaryngol Head Neck Surg. 2021 Oct 1;147(10):847-854

- Clinical and Anatomical Factors Affecting Recurrent Laryngeal Nerve Paralysis During Thyroidectomy via Intraoperative Nerve Monitorization

Author : Nurcihan Aygun

Citation : Front Surg. 2022 Apr 28;9:867948

For registration visit

<https://www.riveroute.in/arhnc2022>

Managed by
riveroute
Leaders in Streaming Modules

Organized by



5th Annual Review on Head & Neck Cancers

5th, 6th & 7th August, 2022

6th August 2022

Day 2 Hybrid

03.35 pm - 04.05 pm

Chairpersons : Dr. Mehul Bhansali
Dr. Shaleen Kumar

- Panel Discussion on Thyroid Cancer

Moderator : Dr. Atul Sharma

Panelists : Dr. Madhuri Shimpi

Dr. Kanhu Patro

Dr. Krishna Kumar T

Dr. Pawan Rane

Dr. Vinayak Maka

Dr. Bharath Rangarajan

Dr. Sagar Vaishampayan

04.05 pm - 04.15 pm

TEA/COFFEE BREAK

04.15 pm - 05.15 pm

Session 6: Key Publication on
Recurrent/metastatic Head And Neck Cancer

04.15 pm - 04.25 pm

Chairpersons : Dr. Rajendra Bhalawat
Dr. P K Julka

Reviewer : Dr. Rushabh Kothari

- Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651

Author : Athanassios Argiris

Citation : Annals of Oncology (2021) 32 (suppl_5): S1283-S1346

- Is there a role of local treatment for oligometastatic scchn in the immunotherapy era

Author : Victoria Espeli

Citation : ICHNO-ECHNO 2022:PO-0086

For registration visit

<https://www.riveroute.in/arhnc2022>

Managed by
riveroute
Leaders in Streaming Modules

Organized by



5th Annual Review on Head & Neck Cancers

5th, 6th & 7th August, 2022

6th August 2022

Day 2 Hybrid

04.25 pm - 04.35 pm

Reviewer : Dr. Priya Tiwari

- Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

Author : Joël Guigay

Citation : Lancet Oncol 2021; 22: 463-75

- A phase II trial of pembrolizumab and cabozantinib in patients (pts) with recurrent metastatic head and neck squamous cell carcinoma (RMHNSCC)

Author : Nabil F. Saba

Citation : Journal of Clinical Oncology 2022 40:16_suppl, 6008-6008

04.35 pm - 04.45 pm

Reviewer : Dr. Nandini Menon

- Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck: A Tertiary Cancer Center Experience

Author : Ananya Pareek

Citation : South Asian J Cancer 2021;00:1-4

- Salvage surgery for recurrent squamous cell carcinoma of the head and neck: Systematic review and meta-analysis

Author : Bulbul MG

Citation : Head Neck. 2022 Jan;44(1):275-285

For registration visit

<https://www.riverroute.in/arhnc2022>

Managed by
riverroute
Leaders in Streaming Modules

Organized by



5th Annual Review on Head & Neck Cancers

5th, 6th & 7th August, 2022

6th August 2022

Day 2 Hybrid

04.45 pm - 05.15 pm

**Chairpersons : Dr. Bharat Parikh
Dr. Shekhar Patil**

- Panel Discussion On Recurrent/metastatic Head And Neck Cancer

Moderator : Dr. Ranga Rao

Panelists : Dr. B. Sainath

Dr. Suman Mallik

Dr. Ankhur Bhal

Dr. Ashay Karpe

Dr. Ghanshyam Biswas

Dr. Sadashivudu Gundeti

Dr. Alok Goel

05.15 pm - 06.15 pm

Session 7: Key Publication On Special Population (RARE/HPV/ELDERLY)

**Chairpersons : Dr. S. V. S. S. Prasad
Dr. G. K. Jadhav**

05.15 pm - 05.25 pm

- Reviewer : Dr. Karan Gupta**

A Randomized Trial of Radiotherapy vs. Trans-Oral Surgery for Treatment De-Escalation in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (ORATOR2)

Author : Palma

Citation : International Journal of Radiation Oncology, Biology, Physics, Volume 111, Issue 5, 1324 - 1325

- Surgery For The Treatment of HPV-negative Squamous Cell Carcinoma of The Oropharynx - A Systematic Review And Meta-analysis

Author : Erica H McArdle

Citation : AHNS 2022: Poster: A104

For registration visit

<https://www.riveroute.in/arhnc2022>

Managed by
riveroute
Leaders in Streaming Modules

Organized by



5th Annual Review on Head & Neck Cancers

5th, 6th & 7th August, 2022

6th August 2022

Day 2 Hybrid

05.25 pm - 05.35 pm

Reviewer : Dr. Deepanjali Adulkar

- Hypofractionated Vs standard radiotherapy in elderly unfit patients with HN cancer- ELAN-RT trial

Author : Cecile ortholan

Citation : ICHNO-ECHNO 2022: OC-0012

- Long-Term Results for MC1273, A Phase II Evaluation of De-Escalated Adjuvant Radiation Therapy for Human Papillomavirus Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC)

Author : Ma, D.J. et al.

Citation : International Journal of Radiation Oncology, Biology, Physics, Volume 111, Issue 3, S61

05.35 pm - 05.45 pm

Reviewer : Dr. Babita Kataria

- Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥ 70 years) with squamous cell carcinoma of the head and neck

Author : Saleh, Khalil et al.

Citation : European Journal of Cancer, Volume 157, 190 - 197

- Detectable Postoperative Circulating Tumor Human Papillomavirus DNA and Association with Recurrence in Patients With HPV-Associated Oropharyngeal Squamous Cell Carcinoma

Author : Routman, David M. et al.

Citation : International Journal of Radiation Oncology, Biology, Physics, Volume 113, Issue 3, 530 - 538

For registration visit

<https://www.riverroute.in/arhnc2022>

Managed by
riverroute
Leaders in Streaming Modules

Organized by



5th Annual Review on Head & Neck Cancers

5th, 6th & 7th August, 2022

6th August 2022

Day 2 Hybrid

05.45 pm - 06.15 pm

**Chairpersons : Dr. Arnab Gupta
Dr. Deepak Sarin**

• Panel Discussion On Special Population
(RARE/HPV/ELDERLY)

Moderator : Dr. Dushyant Mandlik

**Panelists : Dr. Nikhilesh Borkar
Dr. Rakesh Katna
Dr. Venkata Pradeep Babu
Dr. Shailesh Bondarde
Dr. Chakor Vora
Dr. Gautam Sharan**

Sponsored Session

06.15 pm - 06.35 pm

• TBA

06.35 pm - 06.50 pm

• Individualizing patient journey in RM SCCHN
(Supported by Merck)
Speaker : Dr. Suhas Agre

06.50 pm - 07.05 pm

• Approach to Salivary Gland tumor and Role
of anti-HER2 therapy (Supported by Zydus)
Speaker : Dr. Vijay Patil
(Supported by DRL)
Chairperson : Dr. Nagraj Huilgol

07.05 pm - 07.15 pm

• Radiation Dermatitis the unwelcome
consequence of a life saving therapy
Speaker : Dr. Anuj Kumar S

07.15 pm - 07.30 pm

• Strata XRT: A novel full contact silicone-based
gel dressing in prevention and treatment of
Radiation Dermatitis
Speaker : Dr. Ajau Rao

07.30 pm - 07.35 pm

• Q & A

For registration visit

<https://www.riveroute.in/arhnc2022>

Managed by
riveroute
Leaders in Streaming Modules

Organized by



5th Annual Review on Head & Neck Cancers

5th, 6th & 7th August, 2022

6th August 2022 — Day 2 Hybrid

- | | |
|---------------------|--|
| 07.35 pm - 07.50 pm | • Advances in Novel Formulations of Taxanes in Head & Neck Cancer (Supported by Intas)
Speaker : Dr. Vijay Patil |
| 07.50 pm - 08.05 pm | • Personalised Therapy in Treatment of BRAF V600E mutated Anaplastic Thyroid Cancer (Supported by Novartis)
Speaker : Dr. Vijay Patil |

For registration visit

<https://www.riveroute.in/arhnc2022>

Managed by
riveroute
Leaders in Streaming Modules

Organized by



5th Annual Review on Head & Neck Cancers

5th, 6th & 7th August, 2022

7th August 2022

Day 3 Hybrid

09.50 am - 09.55 am

Reviewer : Dr. Arun Balaji

Long-term swallowing-related outcomes in oral cancer patients receiving proactive swallowing therapy

Author : Wen-Hsuan Tseng

Citation : Oral Oncol. 2021 Nov;122:105569

09.55 am - 10.05 am

Q & A

10.05 am - 11.05 am

Session 9: Key Publication on Locally Advanced-HN&SCC

10.05 am - 10.15 am

**Chairpersons : Dr. Govind Babu
Dr. A K Anand**

Reviewer : Dr. Bhuvan Chugh

Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial

Author : Jean Bourhis

Citation : Annals of Oncology (2021)

32 (suppl_5): S1283-S1346

Paclitaxel Based CCRT Is an Acceptable Alternative for Cisplatin Based CCRT in the Treatment of Locally Advanced (Stage IVA) Head Neck Carcinoma

Author : Md. Zillur Rahman Bhuiyan

Citation : Cancer Research Journal.2021; 9(3): 166-170

For registration visit

<https://www.riverroute.in/arhnc2022>

Managed by
riverroute
Leaders in Streaming Modules

Organized by



5th Annual Review on Head & Neck Cancers

5th, 6th & 7th August, 2022

7th August 2022

Day 3 Hybrid

10.15 am - 10.25 am

Reviewer : Dr. Kumardeep Dutta

• The role of induction chemotherapy in patients with locally advanced head and neck squamous cell carcinoma: A nationwide population-based matched study

Author : Meng-Che Hsieh

Citation : Oral Oncol. 2022 May;128:105848

• Quality of life in patients with locally advanced head and neck cancer treated with concurrent chemoradiation with cisplatin and nimotuzumab versus cisplatin alone – Additional data from a phase 3 trial

Author : Nandini Menon

Citation : Oral Oncol. 2021 Nov;122:105517

10.25 am - 10.35 am

Reviewer : Dr. Rakesh Pinninti

• Six-year follow-up from the weekly-three-weekly study comparing cisplatin once-a-week to once-every-three-weeks as concurrent chemoradiation for locally advanced head and neck squamous cell carcinoma

Author : Vanita Noronha

Citation : Journal of Clinical Oncology 2022 40:16_suppl, 6071-6071

• A randomized phase II study evaluating concurrent or sequential fixed-dose immune therapy in combination with cisplatin and intensity-modulated radiotherapy in intermediate- or high-risk, previously untreated, locally advanced head and neck cancer (LA SCCHN)

Author : David Anthony Clump

Citation : Journal of Clinical Oncology 2022 40:16_suppl, 6007-6007

For registration visit

<https://www.riverroute.in/arhnc2022>

Managed by
riverroute
Leaders in Streaming Modules

Organized by



5th Annual Review on Head & Neck Cancers

5th, 6th & 7th August, 2022

7th August 2022

Day 3 Hybrid

10.35 am - 11.05 am	Chairpersons : Dr. A K Dewan Dr. Manisha Singh
10.35 am - 11.05 am	• Panel Discussion on Locally Advanced-HN&SCC Moderator : Dr. Nandini Menon Panelists : Dr. Simon Pavamani Dr. Munish Gairola Dr. Sachin Hingmire Dr. Ram Abhinav Dr. Tanmoy Mandal Dr. Vijay Sharnangat
11.05 am - 11.20 am	TEA/COFFEE BREAK
11.20 am - 11.50 am	Session 10: Key Publication on Biomarkers in H&N Cancer
11.20 am - 11.50 am	• Chairperson : Dr. Anurag Mehta Reviewer : Dr. Neha Mittal Key Publication on Biomarkers in H&N Cancer
11.50 am - 12.15 pm	Session 11: HEAD AND NECK CANCERS : Interventions and Others
11.50 am - 12.00 pm	• Chairpersons : Dr. Vijay Haribhakti Dr. Nagraj Huilgol Reviewer : Dr. Rahul Kulkarni Aspiration pneumonia in head and neck cancer patients undergoing concurrent chemoradiation from India: Findings from a post hoc analysis of a phase 3 study Author : Patil V Citation : Cancer Medicine 2021;10:6725-35

For registration visit

<https://www.riveroute.in/arhnc2022>

Managed by
riveroute
Leaders in Streaming Modules

Organized by



5th Annual Review on Head & Neck Cancers

5th, 6th & 7th August, 2022

7th August 2022

Day 3 Hybrid

12.00 pm - 12.10 pm

• Post hoc analysis of the screening log of phase III investigator-initiated randomized clinical trial comparing palliative oral metronomic versus intravenous chemotherapy in head-and-neck cancer

Author : Sachin Dhumal

Citation : Cancer Res Stat Treat 2021;4:642-6

Reviewer : Dr. Rakesh Roy

• Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer: A Systematic Review and Meta-analysis

Author : Razan Masarwy

Citation : JAMA Otolaryngol Head Neck Surg. 2021 Oct 1;147(10):871-878

• Prognostic factor analysis and long-term results of the TAX 323 (EORTC 24971) study in unresectable head and neck cancer patients

Author : Petr Szturz

Citation : Eur J Cancer. 2021 Oct;156:109-118

12.10 pm - 12.15 pm

Reviewer : Dr. Anshul Singla

• A Multi-Institutional Analysis of Late Complications In Scapula, Fibula, and Osteocutaneous Radial Forearm Free Flap

Author : Craig A Bollig

Citation : AHNS 2022: Oral Paper: AHNS33

12.15 pm Onwards

Industrial Symposium and Vote of Thanks Followed by Lunch

For registration visit

<https://www.riverroute.in/arhnc2022>

Managed by
riverroute
Leaders in Streaming Modules

Organized by



5th Annual Review on Head & Neck Cancers

5th, 6th & 7th August, 2022

Conference Secretariat

Yash Jain

Mobile No: 7718950974 | E-mail: rrcg.yash@gmail.com

River Route Creative Group

Mumbai

Mobile No: 7718950974 | Email id: rrcg.yash@gmail.com

For registration visit

<https://www.riverroute.in/arhnc2022>

Managed by
riverroute
Leaders in Streaming Modules

Organized by



5th Annual Review on Head & Neck Cancers

5th, 6th & 7th August, 2022

7th August 2022

Day 3 Hybrid

09.30 am - 10.05 am

Session 8: Key Publication in Supportive Care

**Chairpersons : Dr. Anuradha Daptardar
Dr. Sharad Desai**

09.30 am - 09.40 am

Reviewer : Dr. Mansi Khanderia

Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Prophylactic Gabapentin for the Reduction of Oral Mucositis Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma

Author : Cook, Andrew et al.

Citation : International Journal of Radiation Oncology, Biology, Physics, Volume 112, Issue 4, 926 - 937

Use of Prophylactic Steroids to Prevent Hypocalcemia and Voice Dysfunction in Patients Undergoing Thyroidectomy A Randomized Clinical Trial

Author : Adeel Abbas Dhahri

Citation : JAMA Otolaryngol Head Neck Surg. 2021;147(10):866-870

09.40 am - 09.50 am

Reviewer : Dr. Y. T. Shivshankar

Use of deep learning to predict the need for aggressive nutritional supplementation during head and neck radiotherapy

Author : Michael Dohopolski

Citation : Radiother Oncol. 2022 Jun;171:129-138

Nutritional Support During Radiotherapy for Head and Neck Cancer: The Role of Prophylactic Feeding Tube Placement

Author : Jormain Cady

Citation : Clin J Oncol Nurs. 2007 Dec;11(6):875-80

For registration visit

<https://www.riveroute.in/arhnc2022>

Managed by
riveroute
Leaders in Streaming Modules